Peptides for alcohol use disorder

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Alcohol Use Disorder: Novel Approaches to Reduce Cravings and Relapse Alcohol Use Disorder (AUD) affects approximately 14.5 million adults in the United States, yet only a fraction receive treatment, and relapse rates remain high even...

Peptides for Alcohol Use Disorder: Novel Approaches to Reduce Cravings and Relapse

Alcohol Use Disorder (AUD) affects approximately 14.5 million adults in the United States, yet only a fraction receive treatment, and relapse rates remain high even after intervention [1]. This chronic, relapsing brain disease is characterized by impaired control over alcohol use, preoccupation with alcohol, and continued use despite adverse consequences. Traditional pharmacotherapies, such as naltrexone, acamprosate, and disulfiram, offer some benefit but often have limited efficacy or significant side effects, driving the search for novel therapeutic targets. Peptides, with their ability to modulate reward pathways, stress responses, and neuroinflammation, present a promising new frontier in AUD treatment.

The neurobiology of AUD involves complex alterations in brain reward circuitry, particularly the dopamine system, and dysregulation of stress and anti-stress systems [2]. Neuropeptides play a crucial role in mediating these processes. For instance, the hypocretin/orexin system, a neuropeptide system, is known to regulate motivation for drugs of abuse, including alcohol, suggesting its modulation could reduce alcohol-seeking behaviors [3]. Similarly, neuropeptide S (NPS) and galanin have been implicated in alcohol and cocaine seeking, highlighting the broad involvement of peptides in addiction.

One peptide gaining attention is Spexin (SPX), also known as neuropeptide Q. This 14-amino acid neuropeptide has shown promise in preclinical studies for its ability to lower the urge to consume alcohol. Research from Columbia University has identified Spexin as a potential pharmaceutical therapy for AUD, demonstrating its capacity to reduce alcohol intake in animal models [4]. While human clinical trials are still in early stages, the mechanism of action appears to involve modulating neural circuits that drive alcohol-seeking behaviors. Specific dosing for Spexin in AUD is yet to be established in human trials.

Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications primarily used for type 2 diabetes and obesity, are emerging as potential treatments for AUD. Semaglutide, a GLP-1 receptor agonist, has shown significant promise in reducing heavy drinking and alcohol craving. A preliminary phase 2 clinical trial found that once-weekly semaglutide led to greater reductions in heavy drinking and weekly alcohol craving over time [5]. GLP-1 receptor agonists work by activating GLP-1 receptors in the brain, which are involved in reward processing and appetite regulation, thereby reducing the reinforcing effects of alcohol. Typical doses for semaglutide in other conditions range from 0.25 mg to 2.4 mg once weekly, administered subcutaneously. You'll find that this class of drugs offers a novel approach by targeting metabolic and reward pathways simultaneously.

BPC-157, a stable gastric pentadecapeptide, is widely recognized for its regenerative and cytoprotective properties. While direct clinical trials for BPC-157 in AUD are limited, its influence on the gut-brain axis and modulation of dopaminergic systems could indirectly support individuals in AUD recovery. BPC-157 has been shown to counteract various behavioral disturbances and dopamine system dysregulation in animal models of addiction, suggesting a potential role in mitigating the neurobiological changes associated with chronic alcohol consumption [6]. Its anti-inflammatory and neuroprotective effects could also help repair alcohol-induced damage to the gastrointestinal tract and brain. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 week cycles.

The nuance in utilizing peptides for AUD lies in their ability to target distinct neurobiological pathways compared to traditional pharmacotherapies. For example, naltrexone primarily blocks opioid receptors, reducing the pleasurable effects of alcohol, but does not directly address the underlying neuroinflammation or gut dysbiosis often seen in AUD. Peptides like Spexin and GLP-1 agonists directly influence craving and reward pathways, while BPC-157 supports systemic healing and neuroprotection. It's important to view these peptides as potential adjunctive treatments, working synergistically with established pharmacotherapies and behavioral interventions to provide more comprehensive support for sustained recovery. They are not replacements for detoxification or core AUD treatments but rather complementary tools that can enhance neurobiological resilience.

Comparing peptide interventions to conventional pharmacotherapy, such as oral naltrexone (typically 50 mg daily), reveals different therapeutic targets. Naltrexone reduces the reinforcing effects of alcohol, but may not address the underlying neurobiological vulnerabilities that drive cravings. For a patient with AUD struggling with persistent cravings and difficulty reducing heavy drinking despite adherence to naltrexone, consider an adjunctive trial of once-weekly semaglutide, starting at 0.25 mg and titrating up as tolerated, to specifically target reward pathways and reduce alcohol-seeking behaviors, as it offers a distinct mechanism of action from opioid receptor antagonism.

References

[1] Substance Abuse and Mental Health Services Administration. (2023). Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report

[2] Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238.

[3] Shevchouk, O. T., et al. (2021). An overview of appetite-regulatory peptides in addiction processes; from bench to bed side. Frontiers in Neuroscience, 15, 774050.

[4] Columbia Technology Ventures. (2023). Peptide therapy for alcohol abuse disorder. Retrieved from https://inventions.techventures.columbia.edu/technologies/peptide-therapy-for-alcohol--CU16253

[5] Hendershot, C. S., et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry, 82(4), 314-322.

[6] Sikiric, P. C., et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 475–481.

[7] National Institute on Alcohol Abuse and Alcoholism. (2023). Medications for Alcohol Use Disorder. Retrieved from https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/medications-alcohol-use-disorder